Sat, Feb 28, 2015, 10:16 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Omeros Corporation (OMER) Message Board

  • cjmaranto cjmaranto Oct 15, 2009 4:44 PM Flag

    Question for bashers

    At this point the movement in the stock does not support any of the claims by the bashers. Other than the first day of trading, we have been going down on very light volume which tells me daytraders have been flipping and pulling the stock down. I will hold for the next high volume day whether it is up or down.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • This is conversion of illiquid preferred shares to shares that will have liquidity after 144 expiration. Hope you like being long on this one.

      From their prospectus:

      Preferred Stock
      Our board of directors has the authority, without further action by the shareholders, to
      issue from time to time the preferred stock in one or more series, to fix the number of shares
      of any such series and the designation thereof and to fix the rights, preferences, privileges and
      restrictions granted to or imposed upon such preferred stock, including dividend rights,
      dividend rates, conversion rights, voting rights, rights and terms of redemption, redemption
      prices, liquidation preference and sinking fund terms, any or all of which may be greater than
      or senior to the rights of the common stock. The issuance of preferred stock could adversely
      affect the voting power of holders of common stock and reduce the likelihood that such
      holders will receive dividend payments and payments upon liquidation. Such issuance could
      have the effect of decreasing the market price of the common stock. The issuance of preferred
      stock or even the ability to issue preferred stock could have the effect of delaying, deterring or
      preventing a change in control. We have no present plans to issue any shares of preferred

    • You really need to read the prospectus. You are making an a$$ out of yourself.

      The only thing you got right was the new shares are locked up.

    • What you made was a statement. What we are making is observations. Going down on light volume means there are no buyers.

    • Well Chuckie, you don't sound like someone losing his butt on an IPO one week out. How many shares you alloted?


    • Rough start for the company, but the product pipeline has great potential. Putting aside their surgical platforms which continue in Phase II and III clinical trials, the promise of Omeros' GPCR (G-protein-coupled receptor) program remains high given recent news like this:

      Novartis is paying Heptares $200+ M for an unspecified GPCR even before they've identified a binding drug. According to Omeros they think they can de-orphanize at least 65 of these GPCRs with their technology and have several GPCRs they've already identified both the receptor and a novel targeting drug ready for testing. How much would a company like Novartis pay for combinations like this?

      Some simple due diligence would also show that The Novartis Venture Fund is already an investor in Omeros and would likely already be aware of this advanced GPCR program. Bash the disappointing early start to this company, but don't tell me there's not legitimate long-term potential here.

20.87-0.06(-0.29%)Feb 27 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.